The study indicated that the frequency of partial genomic loss of PSMC2 was 0.10 among 3131 cancers across a wide diversity of cancer types, rendering a high dependence of cancer cells on the remaining PSMC2. This result further suggested PSMC2 could serve as a potential target for cancer treatment. This evidence concerns the gene PSMC2 and cancer.